Abstract
Background and purpose: This study assessed the prevalence of anti-SARS-CoV-2 antibodies in therapeutic immunoglobulin and their impact on serological response to COVID-19 mRNA vaccine in patients with intravenous immunoglobulin (IVIg)-treated chronic immune neuropathies.
Methods: Forty-six samples of different brands or lots of IVIg or subcutaneous IgG were analyzed for anti-SARS-CoV-2 IgG using enzyme-linked immunosorbent assay and chemiluminescent microparticle immunoassay. Blood sera from 16 patients with immune neuropathies were prospectively analyzed for anti-SARS-CoV-2 IgA, IgG, and IgM before and 1 week after IVIg infusion subsequent to consecutive COVID-19 mRNA vaccine doses and after 12 weeks. These were compared to 42 healthy subjects.
Results: Twenty-four (52%) therapeutic immunoglobulin samples contained anti-SARS-CoV-2 IgG. All patients with immune neuropathies (mean age = 65 ± 16 years, 25% female) were positive for anti-SARS-CoV-2 IgG after COVID-19 vaccination. Anti-SARS-CoV-2 IgA titers significantly decreased 12-14 weeks after vaccination (p = 0.02), whereas IgG titers remained stable (p = 0.2). IVIg did not significantly reduce intraindividual anti-SARS-CoV-2 IgA/IgG serum titers in immune neuropathies (p = 0.69). IVIg-derived anti-SARS-CoV-2 IgG did not alter serum anti-SARS-CoV-2 IgG decrease after IVIg administration (p = 0.67).
Conclusions: Our study indicates that IVIg does not impair the antibody response to COVID-19 mRNA vaccine in a short-term observation, when administered a minimum of 2 weeks after each vaccine dose. The infusion of current IVIg preparations that contain anti-SARS-CoV-2 IgG does not significantly alter serum anti-SARS-CoV-2 IgG titers.
Keywords: COVID-19 vaccine; IVIg; anti-SARS-CoV-2 IgG; antibodies; vaccine interaction.
【저자키워드】 antibodies, COVID-19 vaccine, IVIG, anti-SARS-CoV-2 IgG, vaccine interaction., 【초록키워드】 COVID-19, IgG, IgM, Intravenous immunoglobulin, Vaccine, vaccination, mRNA vaccine, anti-SARS-CoV-2, immune, vaccine dose, Prevalence, immunoassay, serum, COVID-19 vaccination, Immunoglobulin, anti-SARS-CoV-2 antibody, IgA, sera, therapeutic, female, Patient, age, serological response, Interaction, IgG titer, administration, dose, observation, healthy subjects, positive, Microparticle, Administered, serum titer, Alter, decrease, enzyme-linked immunosorbent, analyzed, significantly, subsequent, remained, indicate, reduce, impair, the antibody response, IgA titer, 【제목키워드】 immune, COVID-19 vaccination, intravenous,